Ascendis Pharma A (ASND) EBITDA (2014 - 2026)

Ascendis Pharma A has disclosed EBITDA across 13 years of filings, most recently posting $740.4 million for Q1 2026.

• EBITDA for Q1 2026 came in at $740.4 million, up 843.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $633.2 million (down 99.85% YoY), and the FY2025 annual result was -$158.6 million, up 46.75% from the prior year.
• EBITDA came in at $740.4 million for Q1 2026 at Ascendis Pharma A, up from $11.5 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $409.3 billion in Q4 2024 to a low of -$176.0 million in Q3 2023.
• The 5-year median for EBITDA is -$108.8 million (2024), against an average of $24.0 billion.
• Across the five-year window, EBITDA jumped 1039121.01% in 2024 and plunged 100.0% in 2025, its largest moves.
• Ascendis Pharma A's EBITDA stood at -$150.4 million in 2022, then soared by 73.8% to -$39.4 million in 2023, then surged by 1039121.01% to $409.3 billion in 2024, then slumped by 100.0% to $11.5 million in 2025, then surged by 6327.22% to $740.4 million in 2026.
• The last three EBITDA figures came in at $740.4 million (Q1 2026), $11.5 million (Q4 2025), and -$73.1 million (Q3 2025), per Business Quant data.